Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Inotek Pharmaceuticals (ITEK) Stock Price
Media coverage about Inotek Pharmaceuticals (NASDAQ:ITEK) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Inotek Pharmaceuticals earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 44.9714938996268 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Separately, Zacks Investment Research downgraded Inotek Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th.
Shares of Inotek Pharmaceuticals (NASDAQ ITEK) remained flat at $$2.45 during mid-day trading on Wednesday. 180,000 shares of the stock traded hands, compared to its average volume of 1,071,365. The company has a debt-to-equity ratio of 0.97, a current ratio of 27.63 and a quick ratio of 27.63. Inotek Pharmaceuticals has a 52 week low of $0.85 and a 52 week high of $7.40.
COPYRIGHT VIOLATION WARNING: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/12/20/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-inotek-pharmaceuticals-itek-stock-price.html.
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.
Receive News & Ratings for Inotek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.